TY - JOUR T1 - ROMA (registry omalizumab in Malaga): Study of 84 patients JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p274 AU - Monica Martin-Rebollo AU - Alicia Padilla Galo AU - Miranda-Paez Alfonso AU - Levy-Naon Alberto Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p274.abstract N2 - Purpose: Our objective is to describe the patients profile and the results observed in the patients treated with omalizumab in the three main hospitals of Malaga.Methods: Retrospective study of clinical records. All the patients including are adult with not controlled severe allergic asthma condition. A data base has been created using software SPSS 15.0.Results: 84 patients were included (70% women), with an average age of 51 years and FEV1 64.7±18%. The 100% of the patients had some exarcebations and 20% needed hospitalization in the previous year. 9 patients were steroids-dependents. The average time of treatment is of 10.3 months with a mean dose of 306mg/month. When comparing the parameters of control and quality of life (ACT and MINI-AQLQ) and pulmonary function parameters before the treatment and 16 weeks after treatment, we found statistically significant differences (SSD). Also found SSD in the reduction of inhaled and oral steroids, number of exarcebations and hospitalizations.Conclusions: Omalizumab is able to improve the pulmonary function, the control of the asthma and health-related quality of life, decreasing the number of hospitalization and exarcebations, and reducing the use of corticoids (oral and inhaled). ER -